Northside Healthcare System in Atlanta Advances Surgical Robotics Program with Multi-System, Multi-Hospital Agreement for PROCEPT BioRobotics AquaBeam Systems
18 1월 2022 - 9:00PM
PROCEPT BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics
company focused on advancing patient care by developing
transformative solutions in urology, today announced it now has
five AquaBeam Robotic Systems installed across all of Northside
Health Systems’ state-of-the-art surgical facilities.
“I am thrilled that Northside is expanding their
top-ranked surgical robotics program to now include Aquablation
therapy at all five of their hospitals,” stated Lewis S. Kriteman,
M.D., F.A.C.S. partner at Georgia Urology. “As the first surgeon in
Georgia to perform Aquablation therapy, I applaud and thank
Northside for leading the way in providing innovative surgical
techniques to surgeons and expanding access for patients.
Aquablation therapy provides patients a safe and effective BPH
treatment option, regardless of prostate size or shape. I believe
Aquablation therapy is an attractive procedure for patients who
have yet to seek treatment for their BPH symptoms as well as those
who are not satisfied with the results from current surgical or
medical options available to treat BPH.”
“PROCEPT is proud to partner with leading health
systems, such as Northside, that are committed to advancing patient
care through next-generation innovations and we look forward to
supporting their growing programs throughout the greater Atlanta
area,” said Sham Shiblaq, Executive Vice President, Chief
Commercial Officer of PROCEPT. “As we continue to expand our global
commercial footprint, our dedicated team remains focused on
accelerating adoption of Aquablation therapy and bringing this much
needed treatment option to all patients.”
Aquablation therapy combines real-time,
multi-dimensional imaging, automated robotics, and heat-free
waterjet ablation for targeted, controlled, and immediate removal
of prostate tissue. Combining both cystoscopic visualization and
ultrasound imaging, surgeons can create a personalized treatment
plan tailored to each patient’s anatomy. Once the personalized
treatment map is complete, the robotically controlled, heat-free
waterjet ablates the prostate tissue, avoiding critical structures
to preserve sexual function and continence.1,2,3
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics
company focused on advancing patient care by developing
transformative solutions in urology. PROCEPT develops, manufactures
and sells the AquaBeam Robotic System, an advanced, image-guided,
surgical robotic system for use in minimally-invasive urologic
surgery with an initial focus on treating benign prostatic
hyperplasia, or BPH. BPH is the most common prostate disease and
impacts approximately 40 million men in the United States. PROCEPT
designed Aquablation therapy to deliver effective, safe and durable
outcomes for males suffering from lower urinary tract symptoms, or
LUTS, due to BPH that are independent of prostate size and shape or
surgeon experience. PROCEPT has developed a significant and growing
body of clinical evidence, which includes nine clinical studies and
over 100 peer-reviewed publications, supporting the benefits and
clinical advantages of Aquablation therapy.
Forward Looking Statements
This release contains forward‐looking statements
within the meaning of federal securities laws, including statements
regarding the potential utilities, values, benefits and advantages
of Aquablation® therapy performed using PROCEPT’s products,
including AquaBeam® Robotic System, which involve risks and
uncertainties that could cause the actual results to differ
materially from the anticipated results and expectations expressed
in these forward-looking statements. Forward‐looking statements
should not be read as a guarantee of future performance or results
and may not necessarily be accurate indications of the times at, or
by, which such performance or results will be achieved. These
forward‐looking statements are based on PROCEPT’s current
expectations and inherently involve significant risks and
uncertainties. Actual results and the timing of events could differ
materially from those anticipated in such forward‐looking
statements as a result of these risks and uncertainties. These
risks and uncertainties are described more fully in the section
titled “Risk Factors” in PROCEPT’s filings with the Securities and
Exchange Commission (the “SEC”), including PROCEPT’s quarterly
report on Form 10-Q for the quarter ended September 30, on
September 16, 2021. PROCEPT does not undertake any obligation to
update forward‐looking statements and expressly disclaims any
obligation or undertaking to release publicly any updates or
revisions to any forward‐looking statements contained herein. These
forward-looking statements should not be relied upon as
representing PROCEPT’s views as of any date subsequent to the date
of this press release.
Important Safety Information
All surgical treatments have inherent and
associated side effects. The most common side effects are mild and
transient, and may include mild pain or difficulty when urinating,
discomfort in the pelvis, blood in the urine, inability to empty
the bladder or a frequent and/or urgent need to urinate, and
bladder or urinary tract infection. Other risks include ejaculatory
dysfunction and a low risk of injury to the urethra or rectum where
the devices gain access to the body for treatment. For more
information about potential side effects and risks associated with
Aquablation therapy, speak with your urologist or surgeon. No claim
is made that the AquaBeam Robotic System will cure any
medical condition, or entirely eliminate the diseased entity.
Repeated treatment or alternative therapies may sometimes be
required.
1Gilling P. et al. Three-year outcomes after Aquablation therapy
compared to TURP: results from a blinded randomized trial. Can J
Urol. 2020 Feb;27(1):10072-10079.2Desai M, et al. Aquablation for
benign prostatic hyperplasia in large prostates (80-150 cc): 2-year
results. Canadian Journal of Urology. 27(2):10147-10153. Apr
2020.3Bach T. et al. First Multi-Center All-Comers Study for the
Aquablation Procedure. J Clin Med. 2020 Feb;9(2): 603.
Investor Contact:
Gilmartin GroupMatt Bacso, CFAMatt.bacso@gilmartinir.com
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024